The European pharma giant said on Wednesday that its profits and revenues both fell last quarter, thanks largely to the continuing row over its diabetes drug Avandia. It now plans to save £700m in the next three years through outsourcing, job cuts, and cheaper materials.
Outgoing boss JP Garnier wheeled out the standard cliches about ‘streamlining operations’ and ‘identifying new efficiencies’, but those job cuts are bound to dominate headlines. £350m is to be cut from the budget next year alone, so Glaxo workers are in for a nervous few months.
The company’s problems can largely be traced back to a report in an American medical journal last May that claimed Avandia substantially increased the risk of heart attacks. Glaxo has fiercely denied the charge and continues to contest the evidence, but sales of the drug have (not surprisingly) plummeted by more than a third. This was the main reason why total US revenues were a painful 48% down on the previous year.
Meanwhile, the giant company is also being squeezed by competition from generic drug makers. It is clearly hoping that these cost-cutting measures, which will probably mean closing factories and outsourcing work to Eastern Europe or Asia, and also shopping further afield for its materials, will help to make it more lean and mean.
So it looks likely to be an inglorious exit for Garnier, who is widely respected for Glaxo’s success during his tenure. And by the same token, new man Witty faces a tough task. He will take over right in the middle of a painful restructuring, with the company desperate to recover its US sales – an area where he has little or no experience. There is also the very real possibility that the company’s North American bigwigs (both of whom were passed over for the top job) may not stick around to help him out.
Glaxo shareholders will be hoping he can deliver results without any nasty side-effects.